ID
41942
Descripción
Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled out at the Screening Visit, the first and last weekly visits during the cycles of therapy, the cycle observation visits, unscheduled visits, withdrawal visits and the visits at the end of study/treatment.
Link
https://clinicaltrials.gov/ct2/show/NCT00811733
Palabras clave
Versiones (1)
- 19/2/21 19/2/21 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
19 de febrero de 2021
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733
Physical Examination
- StudyEvent: ODM
Descripción
Physical Lymph Node Examination
Alias
- UMLS CUI-1
- C0031809
- UMLS CUI-2
- C0024204
Descripción
Please choose the location of the palpation, then answer the following questions
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0030247
- UMLS CUI [1,2]
- C0450429
Descripción
Please record palpable lymph nodes (> = 1.5cm)
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C0522499
Descripción
Please specify the size of the largest palpable lymph node
Tipo de datos
integer
Unidades de medida
- cm
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C0487742
Descripción
Please specify the size of the largest palpable lymph node
Tipo de datos
integer
Unidades de medida
- cm
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C1444754
Descripción
If yes, please specify the size of the largest palpable lymph node
Tipo de datos
integer
Unidades de medida
- cm2
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C0456389
Descripción
Physical Organ Exam
Alias
- UMLS CUI-1
- C0031809
- UMLS CUI-2
- C0178784
Descripción
Hepatomegaly
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0019209
Descripción
Liver size below costal margin
Tipo de datos
integer
Unidades de medida
- cm
Alias
- UMLS CUI [1,1]
- C0456389
- UMLS CUI [1,2]
- C0023884
- UMLS CUI [1,3]
- C0542339
- UMLS CUI [1,4]
- C1288448
Descripción
Splenomegaly
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0038002
Descripción
Spleen size below costal margin
Tipo de datos
integer
Unidades de medida
- cm
Alias
- UMLS CUI [1,1]
- C0037993
- UMLS CUI [1,2]
- C0456389
- UMLS CUI [1,3]
- C0542339
- UMLS CUI [1,4]
- C1288448
Similar models
Physical Examination
- StudyEvent: ODM
C2985720 (UMLS CUI [2])
C0024204 (UMLS CUI-2)
C0450429 (UMLS CUI [1,2])
C0522499 (UMLS CUI [1,2])
C0487742 (UMLS CUI [1,2])
C1444754 (UMLS CUI [1,2])
C0456389 (UMLS CUI [1,2])
C0023884 (UMLS CUI [1,2])
C0542339 (UMLS CUI [1,3])
C1288448 (UMLS CUI [1,4])
C0456389 (UMLS CUI [1,2])
C0542339 (UMLS CUI [1,3])
C1288448 (UMLS CUI [1,4])
Sin comentarios